Aarti Pharmalabs Limited Stock Price Today (NSE: AARTIPHARM)
Fundamental Score
Aarti Pharmalabs Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Aarti Pharmalabs Limited share price today is ₹813.00, up +2.98% on NSE/BSE as of 16 September 2026. Aarti Pharmalabs Limited (AARTIPHARM) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹7.37K (Cr). The 52-week high for AARTIPHARM share price is ₹946.10 and the 52-week low is ₹585.00. At a P/E ratio of 34.58x, AARTIPHARM is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 8.40% and a debt-to-equity ratio of 0.32.
Aarti Pharmalabs Limited Share Price Chart — NSE/BSE Historical Performance
Aarti Pharmalabs Limited share price chart: 0.81% return over the past month. 52-week high ₹946.10, 52-week low ₹585.00.
Aarti Pharmalabs Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹785.00 | ₹819.80 | ₹765.00 | ₹813.00 | 3.79L (Cr) | |
| ₹831.95 | ₹832.00 | ₹785.15 | ₹789.45 | 3.86L (Cr) | |
| ₹814.00 | ₹833.00 | ₹814.00 | ₹826.95 | 2.69L (Cr) | |
| ₹836.00 | ₹839.00 | ₹814.00 | ₹825.75 | 2.85L (Cr) | |
| ₹866.00 | ₹873.00 | ₹820.50 | ₹829.65 | 5.58L (Cr) | |
| ₹866.90 | ₹889.70 | ₹861.55 | ₹867.00 | 4.53L (Cr) | |
| ₹861.00 | ₹894.70 | ₹856.35 | ₹862.65 | 7.45L (Cr) | |
| ₹872.00 | ₹879.75 | ₹854.10 | ₹858.80 | 4.63L (Cr) | |
| ₹867.25 | ₹886.95 | ₹854.50 | ₹868.10 | 3.79L (Cr) | |
| ₹866.00 | ₹879.40 | ₹859.50 | ₹867.25 | 3.44L (Cr) |
Aarti Pharmalabs Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹845.00 | ₹894.70 | ₹765.00 | ₹813.00 | -3.79% | |
| ₹670.80 | ₹932.60 | ₹670.65 | ₹845.40 | +26.03% | |
| ₹684.95 | ₹735.00 | ₹650.80 | ₹667.15 | -2.60% | |
| ₹635.00 | ₹743.60 | ₹604.15 | ₹680.05 | +7.09% | |
| ₹751.35 | ₹814.00 | ₹626.00 | ₹633.25 | -15.72% | |
| ₹610.00 | ₹753.40 | ₹610.00 | ₹740.25 | +21.35% | |
| ₹681.00 | ₹714.95 | ₹585.00 | ₹591.95 | -13.08% | |
| ₹737.20 | ₹803.50 | ₹678.60 | ₹723.70 | -1.83% | |
| ₹752.40 | ₹817.90 | ₹723.15 | ₹753.20 | +0.11% | |
| ₹697.10 | ₹784.25 | ₹685.30 | ₹752.40 | +7.93% | |
| ₹847.70 | ₹869.85 | ₹672.70 | ₹700.65 | -17.35% | |
| ₹828.50 | ₹875.00 | ₹820.00 | ₹851.95 | +2.83% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Aarti Pharmalabs Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Aarti Pharmalabs Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AARTIPHARM across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (19.55%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (53.82%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (38.74%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Interest Coverage (5.80x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 2.01)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Risk Factors
2 factors identified
Below-Average Return on Equity (8.40%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Negative Free Cash Flow (₹-296.58 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Aarti Pharmalabs Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Aarti Pharmalabs Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Aarti Pharmalabs LimitedAarti Pharmalab...Selected✓ AARTIPHARM • 543748 | 9.1/100 | ₹813.00₹813 | ₹7372.27₹7372.27 | 34.58Average 34.6 Average | 8.40%Poor 8.40% Poor | 11.34%Average 11.34% Average | 0.32Excellent 0.3 Excellent | — — | — — | 0.70% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Aarti Pharmalabs Limited PE Ratio History
Historical price-to-earnings ratio for AARTIPHARM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹30.04 | ₹752.40 | 25x |
| FY 2024 | ₹23.93 | ₹686.25 | 28.7x |
| FY 2023 | ₹21.35 | ₹504.45 | 23.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Aarti Pharmalabs Limited Dividend History
Annual cash dividends paid by AARTIPHARM — dividend yield 0.70%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹31.72 Cr |
| FY 2024 | ₹18.13 Cr |
| FY 2023 | ₹18.13 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Aarti Pharmalabs Limited Quarterly Performance
Latest quarterly metrics for AARTIPHARM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
38.74%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
53.82%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Aarti Pharmalabs Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AARTIPHARM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Aarti Pharmalabs Limited Financial Statements
Annual income statement, balance sheet and cash flow for Aarti Pharmalabs Limited (AARTIPHARM) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Aarti Pharmalabs Limited
About AARTIPHARM (Aarti Pharmalabs Limited)
Aarti Pharmalabs Ltd is a dynamic force within the global pharmaceutical arena, a company deeply rooted in innovation and dedicated to the development, production, and distribution... of high-quality pharmaceutical solutions. Focused on manufacturing excellence, they specialize in a diverse portfolio of Active Pharmaceutical Ingredients (APIs) and advanced pharmaceutical intermediates, serving as a crucial partner for pharmaceutical companies worldwide. Their commitment to stringent quality control measures, coupled with state-of-the-art manufacturing facilities, ensures that they consistently meet and exceed the exacting standards of the industry. This dedication extends beyond product quality, encompassing a strong emphasis on environmental responsibility and sustainable manufacturing practices. The company's comprehensive product range caters to a multitude of therapeutic areas, reflecting their ambition to contribute meaningfully to global healthcare needs. From complex chemical syntheses to the efficient scaling of production processes, Aarti Pharmalabs demonstrates expertise in every facet of pharmaceutical development. They leverage advanced technologies and a highly skilled workforce to deliver cost-effective and reliable solutions to their clients. Moreover, their active pursuit of research and development allows them to remain at the forefront of pharmaceutical advancements, constantly exploring new molecules and innovative manufacturing techniques. Their commitment to backward integration strengthens their supply chain. Aarti Pharmalabs Ltd has established a strong international presence. Their global reach and adherence to international regulatory standards reinforces their position as a trusted supplier in the pharmaceutical landscape. Through strategic collaborations and a customer-centric approach, they build lasting relationships with pharmaceutical companies across continents. By continuously investing in their infrastructure and talent pool, Aarti Pharmalabs positions itself for sustained growth and continued success in the ever-evolving pharmaceutical industry. With a firm focus on innovation, quality, and sustainability, Aarti Pharmalabs is working to become a trusted partner to its customers.
Company Details
Key Leadership
AARTIPHARM Share Price: Frequently Asked Questions
What is the current share price of Aarti Pharmalabs Limited?
Aarti Pharmalabs Limited (AARTIPHARM) trades at ₹813.00 on NSE and BSE. Market cap ₹7.37K (Cr). Educational data only.
What is the P/E ratio of Aarti Pharmalabs Limited?
Aarti Pharmalabs Limited has a P/E of 34.58x vs industry average 34.89x.
What is the Bull Run score for Aarti Pharmalabs Limited?
Aarti Pharmalabs Limited has a Bull Run score of 9.1/100 based on 25+ financial parameters.
Does Aarti Pharmalabs Limited pay dividends?
Aarti Pharmalabs Limited has a dividend yield of 0.70%. Past dividends don't guarantee future payments.
What is the ROE of Aarti Pharmalabs Limited?
Aarti Pharmalabs Limited has ROE of 8.40%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Aarti Pharmalabs Limited?
Aarti Pharmalabs Limited has debt-to-equity of 0.32.
Is Aarti Pharmalabs Limited a good investment?
Bull Run gives Aarti Pharmalabs Limited a score of 9.1/100. This is not investment advice — consult a SEBI-registered advisor.